Alisol B 23-acetate-induced HepG2 hepatoma cell death through mTOR signaling-initiated G1 cell cycle

来源 :中国癌症研究(英文版) | 被引量 : 0次 | 上传用户:wplyaq
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective:The present study aimed to investigate the molecular events in alisol B 23-acetate (ABA) cytotoxic activity against a liver cancer cell line.Methods:First,we employed a quantitative proteomics approach based on stable isotope labeling by amino acids in cell culture (SILAC) to identify the different proteins expressed in HepG2 liver cancer cells upon exposure to ABA.Next,bioinformatics analyses through DAVID and STRING on-line tools were used to predict the pathways involved.Finally,we applied functional validation including cell cycle analysis and West blotting for apoptosis and mTOR pathway-related proteins to confirm the bioinformatics predictions.Results:We identified 330 different proteins with the SILAC-based quantitative proteomics approach.The bioinformatics analysis and the functional validation revealed that the mTOR pathway,ribosome biogenesis,cell cycle,and apoptosis pathways were differentially regulated by ABA.G1 cell cycle arrest,apoptosis and mTOR inhibition were confirmed.Conclusions:ABA,a potential mTOR inhibitor,induces the disruption of ribosomal biogenesis.It also affects the mTOR-MRP axis to cause G1 cell cycle arrest and finally leads to cancer cell apoptosis.
其他文献
Objective:The objective was to systematically assess lung cancer risk prediction models by critical evaluation of methodology,transparency and validation in ord
Objective:We aim to investigate radiomic imaging features extracted in computed tomography (CT) images to differentiate invasive pulmonary adenocarcinomas (IPAs
Objective:The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus cisplati
期刊
目的 根据成人高等护理学生对护理实践技能的需求和目前成人高等护理教育实验教学现状,提出建设具有成教特色的成人高等护理实验课程体系对策.方法 采用自行设计的问卷,调查3
Objective:To explore the natural history of severe dysplasia/carcinoma in situ (SD/CIS) patients and to evaluate the efficacy of endoscopic treatment to SD/CIS